Bristol-Myers Squibb Company News - October 2026
Bristol Myers Squibb Reports RYZ101 Improves Progression-Free Survival in Phase 3 Trial
Bristol Myers Squibb announced positive topline results from ACTION-1, a Phase 3 study of its radiopharmaceutical therapy RYZ101. The trial evaluated the drug...
🟢 Bristol-Myers Squibb is trading 6% up in pre-market
Bristol-Myers Squibb is trading 6.17% higher at $62.77, with no verified company-specific catalyst identified for the October 12 pre-market rise. - Coverage...
🟢 Bristol-Myers Squibb is trading 10.7% up in after-hours trading
Bristol-Myers Squibb is trading at $65.11, up +10.73% in after-hours trading, but available reports do not confirm the move or identify a verified...